Xeris Biopharma Adds Menassie Taddese to Board
The former Viatris executive joins the Xeris board effective November 2, 2026 and will also serve on its Audit Committee.
Updated on Nov. 2, 2026 in People
Xeris Biopharma has appointed Menassie M. Taddese to its Board of Directors, effective November 2, 2026, the company announced in a press release from Chicago. Taddese will also serve on the Board's Audit Committee.
Why it matters
The appointment adds a senior pharmaceutical executive with international commercial experience to a company that markets three products and is advancing a hypothyroidism treatment candidate. It signals the board's focus on commercial growth and audit oversight as the pipeline develops.
Taddese led a roughly $3 billion Viatris business spanning more than 125 markets and 3,500 employees, and earlier served as CFO of an $8 billion Pfizer business. The announcement does not disclose his compensation or equity terms.
The players
Menassie M. Taddese
Taddese is a pharmaceutical executive with nearly 30 years of global leadership experience, including more than 20 years at Pfizer and recent leadership of Viatris's emerging markets business.
Xeris Biopharma
Xeris Biopharma is a pharmaceutical company that markets Recorlev, Gvoke, and Keveyis and is developing XP-8121, a once-weekly injection for hypothyroidism.
The details
Taddese most recently served as President, Emerging Markets at Viatris and spent more than 20 years at Pfizer, where he held senior roles. He also serves as an independent director and Chair of the Audit Committee at Medexus Pharmaceuticals (TSX: MDP).
Timeline
November 2, 2026: Taddese's appointment to the Xeris Board of Directors takes effect.
Market Landscape
Specialty pharmaceutical companies increasingly recruit board members with large-scale international commercial experience as they expand beyond single products. Taddese's background in emerging-market operations positions Xeris's board to weigh growth beyond its current three commercial products.
For investors tracking Xeris, the addition of an audit-focused director could bear on financial reporting oversight as the company manages its three commercial products. Shareholders and patients will see the practical effects of this change mainly through the company's future commercial and pipeline decisions.
The takeaway
Board appointments that combine commercial scale with audit expertise can signal a company's priorities as it grows. Readers following small-cap biopharma can watch how such directors shape decisions on product launches and pipeline funding.
Further reading
Explore more leadership moves in the People section of our business coverage.
Source note: This article includes information reported by Firstwordpharma.
